Evidence map›Paper›PMID 28110049›Full record

Observational studyClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2017

Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali.

M Sanogo, B Kone, B Diarra, M Maiga, B Baya, A M Somboro, Y S Sarro, A C G Togo, B P P Dembele, D Goita and 15 more

Open access · bronzeAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 3 countries.

M SanogoSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
B KoneSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
B DiarraSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Institute of Tropical Medicine (ITM), Biomedical Department, Antwerp, Belgium. Electronic address: bdiarra@icermali.org.
M MaigaSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA.
B BayaSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
A M SomboroSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Y S SarroSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
A C G TogoSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
B P P DembeleSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
D GoitaSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
A KoneSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
O M'BayeSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
N CoulibalySEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
S DiabateSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
B TraoreSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
M H DialloSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Y I CoulibalyFilariasis Unit of the Malaria Research and Training Centre (MRTC), USTTB, Bamako, Mali.
P SaleebUniversity of Maryland School of Medicine, Baltimore, MD, USA.
M BelsonDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
S OrsegaDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
S SiddiquiDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
M A PolisDivision of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
S DaoSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
R L MurphyDivision of Infectious Diseases, Northwestern University, Chicago, IL, USA.
S DialloSEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.
Université des Sciences, des Techniques et des Technologies de Bamako · MLNational Institute of Allergy and Infectious Diseases · USLeidos (United States) · USNorthwestern University · USUniversity of Bamako · MLUniversity of Maryland, Baltimore · US

Funding

Northwestern University Clinical Trial UnitUM1AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Chad J Achenbach · 2012 to 2026
$24.6M
Northwestern University Clinical Trial UnitU01AI069471 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MURPHY, ROBERT LEO · 2007 to 2011
$12.0M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Host-Pathogen Interactions in a Failing Global lineage of MTBC:M.africanumR01AI110386 · NIAID · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI DIALLO, SOULEYMANE · 2014 to 2018
$1.2M
CCR NIH HHS HHSN261200800001CFIC NIH HHS D43 TW010350NCI NIH HHS HHSN261200800001ENIAID NIH HHS R01 AI110386NIAID NIH HHS U01 AI069471NIAID NIH HHS UM1 AI069471
6 · The paper itself

Abstract

objectivesIn Mali early detection and treatment of multidrug-resistant tuberculosis (MDR-TB) are still challenging due to the cost, time and/or complexity associated with regular tests. Microscopic Observation Drug Susceptibility (MODS) is a low-cost assay validated by WHO in 2010. It is a liquid-culture-based assay to detect the 'cording' characteristic of Mycobacterium tuberculosis complex and to assess susceptibility to both isoniazid and rifampicin defining multidrug-resistant tuberculosis (MDR-TB). In this study we aimed to evaluate the performance of MODS as diagnostic tool compared with a validated method-Mycobacteria Growth Indicator Tube/Antimicrobial Susceptibility Testing/Streptomycin, Isoniazid, Rifampicin and Ethambutol (MGIT/AST/SIRE). METHODS AND

resultsBetween January 2010 and October 2015 we included 98 patients with suspected TB in an observational cohort study. The sensitivity and specificity of MODS assay for detecting TB were respectively 94.12% and 85.71% compared with the reference MGIT/7H11 culture, with a Cohen κ coefficient of 0.78 (95% CI 0.517-1.043). The median time to culture positivity for MODS assay and MGIT (plus interquartile range, IQR) was respectively 8 days (IQR 5-11) and 6 days (IQR 5-6). In detecting patients with MDR-TB, the sensitivity and specificity of MODS assay were respectively 100% and 95.92%. The positive predictive value and negative predictive value were, respectively, 66.7% and 100%. The median turnaround times for obtaining MDR-TB results using MODS assay and MGIT/AST/SIRE was respectively 9 days and 35 days. Hence, the MODS assay rapidly identifies MDR-TB in Mali compared with the MGIT/AST/SIRE.

conclusionAs an easy, simple, fast and affordable method, the MODS assay could significantly improve the management of TB.

Indexed as

AdolescentAdultAntitubercular AgentsCohort StudiesEarly DiagnosisEthambutolFemaleHumansIsoniazidMaleMaliMicrobial Sensitivity TestsMicroscopyMiddle AgedMycobacterium tuberculosisProspective StudiesAntitubercular AgentsEthambutolIsoniazidRifampin7H11 cultureMaliMicroscopic observation and drug susceptibilityMultidrug-resistant tuberculosisMycobacteria Growth Indicator Tube/Antimicrobial Susceptibility Testing/Sterptomycin, Isoniazid, Rifampicin and EthambutolTuberculosis

Identifiers

PMID28110049
PMCPMC5441965
OpenAlexW2576047767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.